openPR Logo
Press release

HIV diagnostics market outlook with industry review and forecasts

03-20-2018 09:02 AM CET | Health & Medicine

Press release from: Global Market Insights, Inc.

HIV diagnostics market outlook with industry review

Global HIV diagnostics market size was $2400 million for 2015 and is predicted to register CAGR of 9.5% during the forecast period. Due to technological innovations in disease diagnostic tests and rapid development of CD4, EID and P24 tests, the global industry is predicted to record an enhanced growth during forecast period.

Simple amplification based assay - a blood diagnostic kit created by Cambridge university scientists received the “Popular Prize “at European Inventor award ceremony held on June 9, 2016 by European patent office. This kit can identify ailments like hepatitis B and HIV within less than 90 minutes by taking blood sample of the patient. The test cost only $17 and is same as pregnancy test where one stripe is positive and second is negative. This kit was used to test 40,000 persons for HIV in rural Africa. According to Helen Lee, who headed the team of Cambridge university researchers to develop the device, said that just a single drop of blood sample helps in detecting and treating the ailments in rural areas.

Request sample copy @ https://www.gminsights.com/request-sample/detail/491

Thailand has become the first Asian nation to eradicate mother to child HIV transmission as per WHO reports achieving a greater milestone in its fight against the dreaded disease. Describing the eradication as an outstanding achievement, WHO said that Thailand was the first nation with large HIV endemic to assure an AIDS free population. This pronouncement is a boost for Thai health workers who have changed the country from one of the Asia’s most HIV ravaged communities to pin up the problem of efficiently handling the disease. According to WHO, routine screening tests conducted for HIV infected pregnant women along with free medication facilities in the country played a key role in preventing transmission of HIV virus from mother to child. The global HIV diagnostics market is segmented into key geographical regions including North America, Asia Pacific, Latin America, Europe and MEA.

North America accounted for biggest revenue share of global HIV diagnostics market for 2015 contributing about $946 million to the total revenue. The factors attributed to the growth of the industry were presence of technologically modernized healthcare support, favourable compensation policies and comparatively high spending on healthcare research activities. The region is predicted to experience enhanced industry demand during the forecast period owing to technological development of portable diagnostic tests.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/491

Asia Pacific HIV diagnostics market is predicted to grow rapidly during forecast period owing to heavy industry demand from countries like China and India and a large percentage of population affected by HIV. It is projected to register a CAGR of 10.7% due to improved healthcare services and growing levels of consciousness about the disease amongst the population of the region.

Key industry players profiled in the report include:
• Abbott Healthcare
• BD Biosciences
• Roche Diagnostics
• Zyomyx Incorporation
• Merck & Company Incorporation
• Bristol-Myers Squibb
• Janssen Therapeutics
• Hologic Incorporation
• Chembio Diagnostic Systems
• Alere Incorporation
• Sysmex Incorporation
• bioMerieux
• Abbvie Incorporation
• Gilead Sciences
• Qiagen
• VIIV Healthcare
• Beckman Coulter
• Apogee Flow Systems Limited
• Partec
• PointCare Technologies Incorporation
• Mylan Incorporation
• Siemens Healthcare
• Cepheid
• Daktari Diagnostics
• Janssen Diagnostics

Report Content

Chapter 1. Methodology and Scope

1.1. Methodology

1.1.1. Initial data exploration

1.1.2. Statistical modeling and forecast

1.1.3. Industry insights and validation

1.2. Data Sources

Chapter 2. Executive Summary

2.1. HIV diagnostics industry 3600 synopsis, 2012 - 2023

2.1.1. Business trends

2.1.2. Regional trends

2.1.3. Application trends

Chapter 3. HIV Diagnostics Industry Insights

3.1. Industry segmentation

3.2. Industry size and forecast, 2012 - 2023

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Favorably regulatory landscape

3.3.1.2. PoC HIV diagnostics development

3.3.1.3. Increasing HIV/AIDS prevalence

3.3.2. Industry pitfalls & challenges

3.3.2.1. Low degree of penetration in undeveloped regional markets

3.4. Growth potential analysis

3.5. Porter’s analysis

3.6. PESTEL analysis

Chapter 4. HIV Diagnostics Product Insights

4.1. HIV diagnostics market share by product, 2015 & 2023

4.2. Antibody tests

4.2.1. Market estimates and forecasts by region, 2012 - 2023

4.2.2. HIV-1 screening

4.2.2.1. Market estimates and forecasts by region, 2012 - 2023

4.2.2.2. ELISA/EIA

4.2.2.2.1. Market estimates and forecasts by region, 2012 - 2023

4.2.2.3. Home access dried blood spot

4.2.2.3.1. Market estimates and forecasts by region, 2012 - 2023

4.2.2.4. Rapid tests

4.2.2.4.1. Market estimates and forecasts by region, 2012 - 2023

4.2.3. HIV-1 confirmatory

4.2.3.1. Market estimates and forecasts by region, 2012 - 2023

4.2.3.2. Western blot

4.2.3.2.1. Market estimates and forecasts by region, 2012 - 2023

4.2.3.3. Indirect immunofluorescent antibody assay (IFA)

4.2.3.3.1. Market estimates and forecasts by region, 2012 - 2023

4.2.3.4. Line immunoassay (Cnf)

4.2.3.4.1. Market estimates and forecasts by region, 2012 – 2023

4.2.3.5. RadioImmuno-Precipitation(RIPA)

4.2.3.5.1. Market estimates and forecasts by region, 2012 – 2023

4.2.4. HIV-2 & group O diagnostic tests

4.2.4.1. Market estimates and forecasts by region, 2012 - 2023

4.2.4.2. Blood antibody test

4.2.4.2.1. Market estimates and forecasts by region, 2012 - 2023

4.2.4.3. DBS test

4.2.4.3.1. Market estimates and forecasts by region, 2012 - 2023

4.2.4.4. Line immunoassay (HIV-2)

4.2.4.4.1. Market estimates and forecasts by region, 2012 – 2023

4.3. Viral identification assays

4.3.1. Market estimates and forecasts by region, 2012 - 2023

4.3.2. P24 antigen tests

4.3.2.1. Market estimates and forecasts by region, 2012 – 2023

4.3.3. Qualitative PCR tests

4.3.3.1. Market estimates and forecasts by region, 2012 - 2023

4.3.4. Viral culture

4.3.4.1. Market estimates and forecasts by region, 2012 – 2023

4.4. CD4 testing

4.4.1. Market estimates and forecasts by region, 2012 - 2023

4.5. Viral load testing

4.5.1. Market estimates and forecasts by region, 2012 - 2023

4.6. Early infant diagnosis

4.6.1. Market estimates and forecasts by region, 2012 - 2023

Chapter 5. HIV Diagnostics Regional Insights

5.1. HIV Diagnostics market share by region, 2015 & 2023

5.2. North America

5.2.1. Market estimates and forecasts by product, 2012 - 2023

5.2.2. U.S.

5.2.2.1. Market estimates and forecasts by product, 2012 - 2023

5.2.3. Mexico

5.2.3.1. Market estimates and forecasts by product, 2012 - 2023

5.3. Europe

5.3.1. Market estimates and forecasts by product, 2012 - 2023

5.3.2. Germany

5.3.2.1. Market estimates and forecasts by product, 2012 - 2023

5.3.3. UK

5.3.3.1. Market estimates and forecasts by product, 2012 - 2023

5.4. Asia Pacific

5.4.1. Market estimates and forecasts by product, 2012 - 2023

5.4.2. China

5.4.2.1. Market estimates and forecasts by product, 2012 - 2023

5.4.3. Japan

5.4.3.1. Market estimates and forecasts by product, 2012 - 2023

5.5. Latin America

5.5.1. Market estimates and forecasts by product, 2012 - 2023

5.5.2. Brazil

5.5.2.1. Market estimates and forecasts by product, 2012 - 2023

5.6. MEA

5.6.1. Market estimates and forecasts by product, 2012 – 2023

5.6.2. South Africa

5.6.2.1. Market estimates and forecasts by product, 2012 - 2023

Chapter 6. Company Profiles

6.1. Abbott Healthcare

6.1.1. Business Overview

6.1.2. Financial Data

6.1.3. Product Landscape

6.1.4. Strategic Outlook

6.2. Alere Inc.

6.2.1. Business Overview

6.2.2. Financial Data

6.2.3. Product Landscape

6.2.4. Strategic Outlook

6.3. Apogee Flow Systems Ltd.

6.3.1. Business Overview

6.3.2. Financial Data

6.3.3. Product Landscape

6.3.4. Strategic Outlook

6.4. BD Biosciences

6.4.1. Business Overview

6.4.2. Financial Data

6.4.3. Product Landscape

6.4.4. Strategic Outlook

6.5. Beckman Coulter

6.5.1. Business Overview

6.5.2. Financial Data

6.5.3. Product Landscape

6.5.4. Strategic Outlook

6.6. bioMerieux

6.6.1. Business Overview

6.6.2. Financial Data

6.6.3. Product Landscape

6.6.4. Strategic Outlook

6.7. Cepheid

6.7.1. Business Overview

6.7.2. Financial Data

6.7.3. Product Landscape

6.7.4. Strategic Outlook

6.8. Chembio Diagnostic Systems

6.8.1. Business Overview

6.8.2. Financial Data

6.8.3. Product Landscape

6.8.4. Strategic Outlook

6.9. Daktari Diagnostics

6.9.1. Business Overview

6.9.2. Financial Data

6.9.3. Product Landscape

6.9.4. Strategic Outlook

6.10. Hologic Inc.

6.10.1. Business Overview

6.10.2. Financial Data

6.10.3. Product Landscape

6.10.4. Strategic Outlook

6.11. Janssen Diagnostics

6.11.1. Business Overview

6.11.2. Financial Data

6.11.3. Product Landscape

6.11.4. Strategic Outlook

6.12. Merck & Co. Inc.

6.12.1. Business Overview

6.12.2. Financial Data

6.12.3. Product Landscape

6.12.4. Strategic Outlook

6.13. Mylan Inc.

6.13.1. Business Overview

6.13.2. Financial Data

6.13.3. Product Landscape

6.13.4. Strategic Outlook

6.14. Partec

6.14.1. Business Overview

6.14.2. Financial Data

6.14.3. Product Landscape

6.14.4. Strategic Outlook

6.15. PointCare Technologies Inc.

6.15.1. Business Overview

6.15.2. Financial Data

6.15.3. Product Landscape

6.15.4. Strategic Outlook

6.16. Qiagen

6.16.1. Business Overview

6.16.2. Financial Data

6.16.3. Product Landscape

6.16.4. Strategic Outlook

6.17. Roche Diagnostics

6.17.1. Business Overview

6.17.2. Financial Data

6.17.3. Product Landscape

6.17.4. Strategic Outlook

6.18. Siemens Healthcare

6.18.1. Business Overview

6.18.2. Financial Data

6.18.3. Product Landscape

6.18.4. Strategic Outlook

6.19. Sysmex Corporation

6.19.1. Business Overview

6.19.2. Financial Data

6.19.3. Product Landscape

6.19.4. Strategic Outlook

6.20. Zyomyx Inc.

6.20.1. Business Overview

6.20.2. Financial Data

6.20.3. Product Landscape

6.20.4. Strategic Outlook

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: https://gminsights.wordpress.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV diagnostics market outlook with industry review and forecasts here

News-ID: 984760 • Views:

More Releases from Global Market Insights, Inc.

Rare Sugar Market Top 3 Trends, Covid-19 Outbreak, Factors Driving, Threats, Cha …
Rising awareness regarding health & fitness and the subsequent shift in consumer trends towards low-calorie sweeteners will boost rare sugar market share over the forecast spell. Recent years have marked a steady rise in the prevalence of cardiovascular ailments, diabetes, and obesity, among other chronic conditions, which have triggered a massive change in consumer perceptions towards health. This in turn has led to a surge in demand for various functional foods
Global Selenium Yeast Market Industry Assessment, Trends, Competitive Landscape, …
The selenium yeast market is anticipated to register substantial gains on account of rising inclination towards organic additives in animal nutrition, with an aim to improve livestock health and production. Consumers are steadily becoming aware of the downsides associated with using synthetic additives. As a result, they are preferring selenium yeast feed grades over other counterparts to provide balanced nutrition to their livestock. According to Global Market Insights Inc estimates
Power Distribution Component Market Share, Size, Trends by 2025 | Leading Key players Eaton, Schneider, Siemens, Hitachi, Powell, Hubbell
Power Distribution Component Market Share, Size, Trends by 2025 | Leading Key pl …
Global Power Distribution Component Market Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Request a sample of this research report @ https://www.gminsights.com/request-sample/detail/3091 Voltage rating have acted as a standard industry protocol toward the installation of power components reliant on regulatory preference, deployment areas, and the group
Prenatal Vitamin Ingredients Market New Entrants, Risk Factors, Market Expansion …
The rise in the instances of miscarriages on account of poor diet and hygiene will anchor the consumption of prenatal vitamin ingredients. Excessive intake of junk food has resulted in the scarcity of important nutrients in pregnant women that could adversely affect the fetus health and development. Furthermore, prenatal vitamin ingredients possess additional nutritional components that are not so easily sourced from regular food items and products. Prenatal vitamin ingredients can

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral